User menu

A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells

Bibliographic reference Ayyoub, Maha ; Mazarguil, Honoré ; Monsarrat, Bernard ; Van den Eynde, Benoît ; Gairin, Jean-Edouard. A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells. In: Journal of Biological Chemistry, Vol. 274, no. 15, p. 10227-10234 (1999)
Permanent URL
  1. Boon Thierry, Cerottini Jean-Charles, Van den Eynde Benoit, van der Bruggen Pierre, Van Pel Aline, Tumor Antigens Recognized by T Lymphocytes, 10.1146/annurev.iy.12.040194.002005
  2. Schulz M., Zinkernagel R. M., Hengartner H., Peptide-induced antiviral protection by cytotoxic T cells., 10.1073/pnas.88.3.991
  3. Hu, Cancer Res., 56, 2479 (1996)
  4. Marchand M., Weynants P., Rankin E., Arienti F., Belli F., Parmiani G., Cascinelli N., Bourlond A., Vanwuck R., Humblet Y., Canon J.-L., Laurent C., Naeyaert J.-M., Plagne R., Deraemaeker R., Knuth A., Jager E., Brasseur F., Herman J., Couiae P. G., Boon T., Tumor regression responses in melanoma patients treated with a peptide encoded by geneMAGES-3, 10.1002/ijc.2910630622
  5. Powell Michael F., Grey Howard, Gaeta Federico, Sette Alex, Colón Sonia, Peptide Stability in Drug Development: A Comparison of Peptide Reactivity in Different Biological Media, 10.1002/jps.2600810802
  6. Falo L. D., Colarusso L. J., Benacerraf B., Rock K. L., Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules., 10.1073/pnas.89.17.8347
  7. Ojcius, J. Immunol., 152, 2798 (1994)
  8. Malarkannan, J. Immunol., 154, 585 (1995)
  9. Kozlowski, J. Immunol., 151, 4033 (1993)
  10. Widmann, J. Immunol., 147, 3745 (1991)
  11. Barinaga M, Getting some "backbone": how MHC binds peptides, 10.1126/science.1502554
  12. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, 10.1126/science.1840703
  13. Rammensee Hans-Georg, Friede Thomas, Stevanović Stefan, MHC ligands and peptide motifs: first listing, 10.1007/bf00172063
  14. Hudrisier Denis, Mazarguil Honoré, Laval Fran¸oise, Oldstone Michael B. A., Gairin Jean Edouard, Binding of Viral Antigens to Major Histocompatibility Complex Class I H-2DbMolecules Is Controlled by Dominant Negative Elements at Peptide Non-anchor Residues : IMPLICATIONS FOR PEPTIDE SELECTION AND PRESENTATION, 10.1074/jbc.271.30.17829
  15. Evavold Brian D., Sloan-Lancastert Joanne, Wilson K.Jeff, Rothbard Jonathan B., Allen Paul M., Specific T cell recognition of minimally homologous peptides: Evidence for multiple endogenous Ligands, 10.1016/1074-7613(95)90010-1
  16. Jameson Stephen C., Bevan Michael J., Dissection of major histocompatibility complex (MHC) and T cell receptor contact residues in a Kb-restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs, 10.1002/eji.1830221028
  17. Hudrisier, Curr. Top. Microbiol. Immunol., 232, 75 (1998)
  18. Rognan D., Scapozza L., Folkers G., Daser A., Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigen., 10.1073/pnas.92.3.753
  19. Guichard Gilles, Connan Francine, Graff Roland, Ostankovitch Marina, Muller Sylviane, Guillet Jean-Gérard, Choppin Jeannine, Briand Jean-Paul, Partially Modified Retro-Inverso Pseudopeptides as Non-natural Ligands for the Human Class I Histocompatibility Molecule HLA-A2, 10.1021/jm9509511
  20. Guichard Gilles, Calbo Sébastien, Muller Sylviane, Kourilsky Philippe, Briand Jean-Paul, Abastado Jean-Pierre, Efficient Binding of Reduced Peptide Bond Pseudopeptides to Major Histocompatibility Complex Class I Molecule, 10.1074/jbc.270.44.26057
  21. Lamont, J. Immunol., 144, 2493 (1990)
  22. Maillère Bernard, Mourier Gilles, Cotton Joel, Hervé Mireille, Leroy Sandrine, Ménez André, Probing immunogenicity of a T cell epitope by l-alanine and d-amino acid scanning, 10.1016/0161-5890(95)00073-9
  23. Chen, J. Immunol., 157, 1000 (1996)
  24. Traversari C., A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E, 10.1084/jem.176.5.1453
  25. DiBrino, J. Immunol., 152, 620 (1994)
  26. Romero P., Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1, 10.1084/jem.182.4.1019
  27. Kozlowski S., Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibility complex class I molecules, 10.1084/jem.175.6.1417
  28. Gaugler B., Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes, 10.1084/jem.179.3.921
  29. Powell Michael F., Stewart Tracy, Otvos, Jr Laszlo, Urge Laszlo, Gaeta Federico C. A., Sette Alessandro, Arrhenius Thomas, Thomson David, Soda Ken, Colon Sonia M., 10.1023/a:1018953309913
  30. Verdoliva Antonio, Ruvo Menotti, Cassani Giovanni, Fassina Giorgio, Topological Mimicry of Cross-reacting Enantiomeric Peptide Antigens, 10.1074/jbc.270.51.30422
  31. Guichard G., Benkirane N., Zeder-Lutz G., van Regenmortel M. H., Briand J. P., Muller S., Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics., 10.1073/pnas.91.21.9765
  32. Hervé Mireille, Maillére Bernard, Mourier Gilles, Texier Catherine, Leroy Sandrine, Ménez Andre, On the immunogenic properties of retro-inverso peptides. Total retro-inversion of T-Cell epitopes causes a loss of binding to MHC II molecules, 10.1016/s0161-5890(97)00004-7
  33. Garboczi David N., Ghosh Partho, Utz Ursula, Fan Qing R., Biddison William E., Wiley Don C., Structure of the complex between human T-cell receptor, viral peptide and HLA-A2, 10.1038/384134a0
  34. Kondo Akihiro, Sidney John, Southwood Scott, del Guercio Marie-France, Appella Ettore, Sakamoto Hiroshi, Grey Howard M., Celis Esteban, Chesnut Robert W., Kubo Ralph T., Sette A., Two distinct HLA-A * 0101-specific submotifs illustrate alternative peptide binding modes, 10.1007/s002510050200
  35. Huang A. Y., Gulden P. H., Woods A. S., Thomas M. C., Tong C. D., Wang W., Engelhard V. H., Pasternack G., Cotter R., Hunt D., Pardoll D. M., Jaffee E. M., The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product., 10.1073/pnas.93.18.9730
  36. Valmori, J. Immunol., 160, 1750 (1998)
  37. Aichele P., T cell priming versus T cell tolerance induced by synthetic peptides, 10.1084/jem.182.1.261
  38. Toes R. E., Offringa R., Blom R. J., Melief C. J., Kast W. M., Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction., 10.1073/pnas.93.15.7855
  39. Fairchild Paul J., Wraith David C., Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC, 10.1016/0167-5699(96)80584-6
  40. Kelly Adrian, Powis Stephen H., Kerr Lesley-Anne, Mockridge Ian, Elliott Timothy, Bastin Judy, Uchanska-Ziegler Barbara, Ziegler Andreas, Trowsdale John, Townsend Alain, Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex, 10.1038/355641a0
  41. Traversari Catia, van der Bruggen Pierre, Van den Eynde Benoît, Hainaut Philippe, Lemoine Carine, Ohta Nobuyoshi, Old Lloyd, Boon Thierry, Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes, 10.1007/bf00185107
  42. Hudrisier Denis, Mazarguil Honoré, Oldstone Michael B.A., Gairin Jean Edouard, Relative implication of peptide residues in binding to major histocompatibility complex class I H-2Db: application to the design of high-affinity, allele-specific peptides, 10.1016/0161-5890(95)00043-e
  43. Madden D, The antigenic identity of peptide-MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2, 10.1016/0092-8674(93)90490-h
  44. Boon Thierry, Tumor antigens recognized by cytolytic T lymphocytes: Present perspectives for specific immunotherapy, 10.1002/ijc.2910540202
  45. Melief C, Peptide-based cancer vaccines, 10.1016/s0952-7915(96)80081-1
  46. Jäeger Elke, Bernhard Helga, Romero Pedro, Ringhoffer Mark, Arand Michael, Karbach Julia, Ilsemann Christiane, Hagedorn Manfred, Knuth Alexander, Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptidesin vivo: Implications for tumor vaccines with melanoma-associated antigens, 10.1002/(sici)1097-0215(19960410)66:2<162::aid-ijc4>;2-0
  47. Mandelboim Ofer, Vadai Ezra, Fridkin Mati, Katz-Hillel Anne, Feldman Michael, Berke Gideon, Eisenbach Lea, Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides, 10.1038/nm1195-1179
  48. Rosenberg Steven A., Yang James C., Schwartzentruber Douglas J., Hwu Patrick, Marincola Francesco M., Topalian Suzanne L., Restifo Nicholas P., Dudley Mark E., Schwarz Susan L., Spiess Paul J., Parkhurst Maria R., Kawakami Yutaka, Seipp Claudia A., Einhorn Jan H., White Donald E., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, 10.1038/nm0398-321